Fleischli Christoph, Verhaagh Sandra, Havenga Menzo, Sirena Dominique, Schaffner Walter, Cattaneo Roberto, Greber Urs F, Hemmi Silvio
Institute of Molecular Biology Zürich, Switzerland.
J Virol. 2005 Aug;79(15):10013-22. doi: 10.1128/JVI.79.15.10013-10022.2005.
The human regulator of complement activation membrane cofactor protein (CD46) has recently been identified as an attachment receptor for most species B adenoviruses (Ads), including Ad type 3 (Ad3), Ad11, and Ad35, as well as species D Ad37. To characterize the interaction between Ad35 and CD46, hybrid receptors composed of different CD46 short consensus repeat (SCR) domains fused to immunoglobulin-like domains of CD4 and a set of 36 CD46 mutants containing semiconservative changes of single amino acids within SCR domains I and II were tested in binding and in Ad35-mediated luciferase transduction assays. In addition, anti-CD46 antibodies and soluble polypeptides constituting various CD46 domains were used in binding inhibition studies. Our data indicate that (i) CD46 SCR I or SCR II alone confers low but significant Ad35 binding; (ii) the presence of SCR I and II is required for optimal binding and transgene expression; (iii) transduction efficiencies equivalent to that of full-length CD46 are obtained if SCR I and II are at an appropriate distance from the cell membrane; (iv) ablation of the N-glycan attached to SCR I has no influence on receptor function, whereas ablation of the SCR II N-glycan results in about a two- to threefold reduction of binding and transgene expression; (v) most putative Ad35 binding residues are located on the same solvent-exposed face of the SCR I or SCR II domain, which are twisted by about 90 degrees ; and (vi) the putative Ad35 binding sites partly overlap with the measles virus binding surface.
人类补体激活调节因子膜辅因子蛋白(CD46)最近被确定为大多数B组腺病毒(Ads)的附着受体,包括3型腺病毒(Ad3)、11型腺病毒和35型腺病毒,以及D组腺病毒37型。为了表征Ad35与CD46之间的相互作用,我们测试了由不同的CD46短共识重复序列(SCR)结构域与CD4的免疫球蛋白样结构域融合而成的杂交受体,以及一组36个CD46突变体,这些突变体在SCR结构域I和II内含有单个氨基酸的半保守变化,并进行了结合和Ad35介导的荧光素酶转导测定。此外,抗CD46抗体和构成各种CD46结构域的可溶性多肽被用于结合抑制研究。我们的数据表明:(i)单独的CD46 SCR I或SCR II赋予低但显著的Ad35结合能力;(ii)SCR I和II的存在是最佳结合和转基因表达所必需的;(iii)如果SCR I和II与细胞膜保持适当距离,则可获得与全长CD46相当的转导效率;(iv)去除附着在SCR I上的N-聚糖对受体功能没有影响,而去除SCR II N-聚糖会导致结合和转基因表达降低约两到三倍;(v)大多数假定的Ad35结合残基位于SCR I或SCR II结构域的同一溶剂暴露面上,这些面扭曲了约90度;(vi)假定的Ad35结合位点部分与麻疹病毒结合表面重叠。